Clinical trials: ctDNA
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- APOLO (NCT04776447)
- Testing
- Carboplatin, Placlitaxel, Atezolizumab
- Where
- 22 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundación GECP
Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in…
- Conditions
- Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage III Endometrial Cancer
- Trial name
- NCT07062016
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the…
- Conditions
- Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT04574635
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Ovarian Cancer
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of…
- Trial name
- NCT03614689
- Where
- 6 sites in China
- Volunteers
- 104 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
BRAF V600E Mutation
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with…
- Trial name
- NCT06610682
- Testing
- Plixorafenib, Retifanlimab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oropharynx Squamous Cell Carcinoma
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures.
- Trial name
- SURVEILLE-HPV (NCT05582122)
- Testing
- HPV16 Ct-DNA dosing
- Where
- 16 sites in France
- Volunteers
- 420 people
- Sponsor
- UNICANCER
Uterine Cervical Neoplasm
ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer
This study aims to evaluate the clinical feasibility of first-line immunochemotherapy for stage IVB and recurrent cervical cancer guided by circulating tumor DNA (ctDNA), in order to explore the optimal treatment duration or…
- Trial name
- NCT06878196
- Testing
- cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
ctDNA, Colorectal Cancer (CRC)
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with stage I or low-risk stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Colorectal Cancer (CRC), Adjuvant Chemotherapy
- Trial name
- CLEAR-01 (NCT07562659)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer (CRC)
Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)
This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC…
- Trial name
- RealCHALLENGE (NCT07536113)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Niguarda Hospital
Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment.
- Trial name
- NCT03896620
- Testing
- Preoperative RT, Postoperative RT, Chemotherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Medical College of Wisconsin
Renal Cancer
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as…
- Trial name
- KIDNEY-PAGER (NCT06145139)
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Colorectal Cancer, Liver Metastases
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal…
- Conditions
- Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related
- Trial name
- NCT05797077
- Testing
- Colorectal resection surgery., FOLFOX chemotherapy regimen, Capecitabine
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, MRD
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer.
- Conditions
- Colorectal Cancer, MRD, ctDNA
- Trial name
- NCT07254156
- Testing
- MRD detection
- Where
- China
- Volunteers
- 229 people
- Sponsor
- Sun Yat-sen University
Primary Mediastinal Large B-cell Lymphoma
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of…
- Trial name
- CAMIL (NCT04824950)
- Testing
- Circulating tumor DNA monitoring
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Henri Becquerel
Ovarian Cancer
Study of Circulating Tumoral DNA in Ovarian Cancer
Circulating tumor DNA detection and quantification in patients with ovarian cancer.
- Trial name
- NCT01350908
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Curie
Melanoma
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery Study participants will complete a ctDNA test within 4 weeks…
- Trial name
- NCT05736523
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Pancreatic Cancer, Advanced Cancer
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Advanced Cancer, Metastatic Cancer
- Trial name
- MAP-01 (NCT05802420)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Epithelial Ovarian Cancer
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
- Trial name
- NCT05212779
- Testing
- Signatera testing, Altera Testing
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Immunotherapy, Cervical Cancer
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
Immunotherapy is the main option for advanced, recurrent and metastatic cervical cancer. However, due to the complex interaction between the immune system and tumors, there is still a lack of effective markers for immunotherapy.
- Conditions
- Immunotherapy, Cervical Cancer, CtDNA, Biomarker
- Trial name
- NCT06649838
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
This is a randomized pilot study to evaluate and to compare the completion rates of Total Neoadjuvant chemotherapy with FLOT ( FLOT-TNT) and perioperative chemotherapy with FLOT ( FLOT-POP).
- Trial name
- TOGAR (NCT05567835)
- Testing
- Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine